100
Participants
Start Date
August 1, 2018
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
Diazoxide
"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
Nicotinic acid
T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
Placebo
"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
RECRUITING
Albert Einstein College of Medicine, The Bronx
National Institutes of Health (NIH)
NIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
American Diabetes Association
OTHER
Meredith Hawkins
OTHER